Three Newly Approved Drugs for Chronic Lymphocytic Leukemia: Incorporating Ibrutinib, Idelalisib, and Obinutuzumab Into Clinical Practice
Clinical Lymphoma, Myeloma and Leukemia - United States
doi 10.1016/j.clml.2015.02.019
Full Text
Open PDFAbstract
Available in full text
Date
July 1, 2015
Authors
Publisher
Elsevier BV